Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01982864
Other study ID # I12008 DIAMS
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date October 2013
Est. completion date January 2016

Study information

Verified date July 2020
Source University Hospital, Limoges
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Aminoglycosides are widely used for the treatment of Gram-negative bacilli and Staphylococcus aureus infections because of their effectiveness and low cost. Nevertheless, many aspects of their optimal use in hemodialysis patients remain unsolved and little is known about their pharmacokinetics in this context. The current practice for prescribing aminoglycosides to these particular patients consists in giving after each hemodialysis session about half the dose usually given to patients with normal renal function.

However, theoretical considerations and emerging clinical data suggest that this may not be the most beneficial dosing regimen as efficient peak concentrations are often not attained and the occurrence of ototoxicity and nephrotoxicity is still frequent.


Description:

Recent evidence about the pharmacokinetics and pharmacodynamics of aminoglycosides strongly supports administration of aminoglycosides before, rather than after, hemodialysis. Therapeutic drug monitoring using pharmacokinetic modeling is currently used in non-hemodialysis patients. However, the PK tools employed are not suitable to dialysis patients.

For aminoglycosides, the ratio of peak to Minimal Inhibitory Concentration (MIC) has been shown to be the parameter that best correlates with clinical efficacy, whilst prolonged exposure to high concentrations have been related to either nephrotoxicity or ototoxicity. Additionally, aminoglycosides are mostly excreted as unchanged drugs in urine and their clearance is directly proportional to the glomerular filtration rate. The elimination half-life of aminoglycosides is approximately 1.5-3 hours in adults with normal renal function, but is greatly prolonged up to 36-70 hours in patients with end-stage renal failure. In a standard patient, aminoglycosides are administered as a single dose, over a short time interval, to obtain an elevated blood peak concentration (the effective level). The next injection is not administered before 24 hours, to allow the patient to wash out the aminoside and to minimize the residual blood concentration (the toxic level). The aim here is to maximize the peak concentration during a fair amount of time (by repeating the peaks) and to minimize the overall drug exposure, responsible for the toxicity.

For the renal impaired patient, our hypothesis is that the hemodialyzer can be regarded as a kidney. Thus, the administration of the aminoside at the beginning of the hemodialysis could lead to profiles of elimination comparable to those observed in normorenal patients.

The research aims at performing a population pharmacokinetic (POPPK) study of gentamicin when given to hemodialysis patients.


Recruitment information / eligibility

Status Terminated
Enrollment 24
Est. completion date January 2016
Est. primary completion date January 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- age upper to 18 years

- Patients hospitalized in the "Service de Néphrologie - Hémodialyse, Transplantations, CHU de Limoges"

- Patients requiring chronic hemodialysis

- Patients requiring a treatment by aminoglycosides

- Patients willing to give their written informed consent for their participation to the study

- Patients affiliated to the French social security system or equivalent

Exclusion Criteria:

- Patients under legal protection

- Patients unable or unwilling to provide informed consent and not under legal protection

- Patients deprived of liberty

- Contraindications to gentamicin

- Pregnant or breast-feeding women or women of childbearing potential without efficient contraception (based on declaration)

- Patients with any altered mental status or any psychiatric condition that would interfere with the understanding of the study

- Patients enrolled in another clinical trial testing drugs or therapeutic strategies

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Gentamicin
The decision to introduce the antibiotic is made during a session or between two sessions according to both the clinicians usual procedure. Depending on the number of injections, 8 to 10 blood samples will be drawn per patient. Clinical and biological data will be concomitantly collected (e.g., hemodialysis session duration, creatinine clearance…). The number of blood sampling and the time schedule will be adapted to the prescription and the possible follow-up of the treatment after the first injection. Whatever the time is between the first injection and the following dialysis session, a sampling will be performed 30 minutes after the end of the injection (T1), 8h after the end of the injection (T2), juste before (TAD), in the middle (TMD) and at the end of the dialysis (TFD).

Locations

Country Name City State
France CHU LIMOGES - Laboratoire de Pharmacologie Limoges
France CHU LIMOGES - Service Néphrologie Limoges

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Limoges

Country where clinical trial is conducted

France, 

References & Publications (1)

Franck B, Monchaud C, Saint-Marcoux F, Rérolle JP, Allard J, Allot V, Marquet P, Essig M, Woillard JB. Population pharmacokinetics of gentamicin in haemodialysis patients: modelling, simulations and recommendations. Eur J Clin Pharmacol. 2020 Jul;76(7):94 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Concentration curves of gentamicin The research aims at performing a population pharmacokinetic (POPPK) study of gentamicin when given to hemodialysis patients.
The ability to describe the concentration curves versus time (Biais (%) between the observed concentrations and the concentrations predicted by the model).
1 week
See also
  Status Clinical Trial Phase
Completed NCT01947673 - Mechanisms of Intradialytic Hypertension N/A
Not yet recruiting NCT03634904 - Serum Ceftazidime Concentrations in Hemodialysis Patients N/A
Completed NCT01448174 - Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients Phase 4
Completed NCT01421771 - Blood Pressure in Dialysis Patients N/A
Completed NCT01722695 - Performance Comparison of Revaclear With Larger Dialyzer N/A
Withdrawn NCT01015313 - Effects of Intensified Sodium Management in Hemodialysis Patients N/A
Completed NCT02259413 - Effect of an Exercise Rehabilitation Program on Symptoms in Hemodialysis N/A
Not yet recruiting NCT02452788 - Pharmaceutical Care in Ambulatory Hemodialysis Patients N/A
Recruiting NCT01356563 - Efficacy Study of Pharmacist Intervention on Medication-related Problems in Hemodialysis Patients N/A
Completed NCT01320202 - Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients Phase 3
Completed NCT01181544 - A Pilot Study of a Heparin Dosing Algorithm for Hemodialysis N/A
Completed NCT02285075 - Temocillin Pharmacokinetic in Hemodialysis Phase 4
Completed NCT02825589 - BIA-Guided Dry Weight Assessment on Sleep Quality in Chronic Hemodialysis Patients N/A
Completed NCT00890045 - Hemodialysis Reliable Outflow (HeRO) Vascular Access Patency Study N/A
Not yet recruiting NCT02264964 - Duration and Adverse Events of Non-cuffed Catheter in Patients With Hemodialysis N/A
Completed NCT01214928 - Hemodialysis Vitamin D Pilot N/A
Terminated NCT01312441 - Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D Phase 4
Completed NCT00967993 - Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease Phase 2
Completed NCT01981603 - Transplant Navigator Dissemination N/A
Completed NCT01578421 - Investigation on the Middle Size Molecule Elimination Characteristics of the FXCorDiax 100 in Relation to the FX 100 and the Polyflux 210 H Dialyser N/A